[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342876-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342876-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ppia-dictates-nrf2-stability-to-promote-lung-cancer-progression","PPIA dictates NRF2 stability to promote lung cancer progression","","PPIA (peptidylprolyl isomerase A) is identified as a required factor for NRF2 (nuclear factor erythroid 2-related factor 2) protein stability, linking NRF2 regulation to lung cancer progression. Removing PPIA promotes NRF2 degradation and suppresses NRF2-driven growth in NSCLC cells. Mechanistically, PPIA directly binds NRF2 and blocks ubiquitin/KEAP1 access, preventing ubiquitin-mediated proteolysis. X-ray co-crystal data show an interaction with a trans-proline 174–harboring hydrophobic sequence. The FDA-approved drug cyclosporin A disrupts NRF2–PPIA binding, triggers NRF2 ubiquitination and degradation, interferes with NRF2/KLF5/SLC1A5-linked glutamine metabolism, and restrains growth in patient-derived xenograft models with NRF2 hyperactivation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ppia-dictates-nrf2-stability-to-promote-lung-cancer-progression/342876/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ppia-dictates-nrf2-stability-to-promote-lung-cancer-progression/342876.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does PPIA play in NRF2 regulation?","Question",{"text":63,"@type":64},"PPIA is required for NRF2 protein stability. When PPIA is ablated, NRF2 is degraded more readily and NRF2-driven growth in NSCLC cells is blocked.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PPIA protect NRF2 from ubiquitin-mediated degradation?",{"text":68,"@type":64},"PPIA physically binds NRF2 and blocks ubiquitin/KEAP1 access to NRF2, thereby preventing ubiquitin-mediated degradation.",{"name":70,"@type":61,"acceptedAnswer":71},"What effect does cyclosporin A (CsA) have on NRF2 and lung cancer cells?",{"text":72,"@type":64},"CsA impairs the NRF2–PPIA interaction, inducing NRF2 ubiquitination and degradation. It also disrupts NRF2-linked glutamine metabolism via the NRF2/KLF5/SLC1A5 pathway, suppressing growth of NRF2-hyperactivated NSCLC models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342876,1790193101,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Article [https://doi.org/10.1038/s41467-024-48364-4](https://doi.org/10.1038/s41467-024-48364-4)  \nPPIA dictates NRF2 stability to promote lung cancer progression  \nReceived: 18 May 2023  \nAccepted: 29 April 2024  \n\n| Published online: 03 June 2024 |\n| --- |\n| Check for updates |\n\nWeiqiang Lu 1,2,12 , Jiayan Cui1,12, Wanyan Wang1,12, Qian Hu1,12, Yun Xue 3,4,12, Xi Liu1, Ting Gong1, Yiping Lu1, Hui Ma1, Xinyu Yang2, Bo Feng5, Qi Wang 6,7, Naixia Zhang8, Yechun Xu 8, Mingyao Liu 2, Ruth Nussinov 9,10,  \nFeixiong Cheng 11, Hongbin Ji 3,4 & Jin Huang 1   \nNuclear factor erythroid 2-related factor 2 (NRF2) hyperactivation has been established as an oncogenic driver in a variety of human cancers, including non-small cell lung cancer (NSCLC). However, despite massive efforts, nospeciﬁc therapy is currently available to target NRF2 hyperactivation. Here, we identify peptidylprolyl isomerase A (PPIA) is required for NRF2 protein stability. Ablation of PPIA promotes NRF2 protein degradation and blocks NRF2-driven growth in NSCLC cells. Mechanistically, PPIA physically binds to NRF2 and blocks the access of ubiquitin/Kelch Like ECH Associated Protein 1 (KEAP1) to NRF2, thus preventing ubiquitin-mediated degradation. Our X-ray co-crystal structure reveals that PPIA directly interacts with a NRF2interdomain linker via a trans-proline 174-harboring hydrophobic sequence. We further demonstrate that an FDA-approved drug, cyclosporin A (CsA), impairs the interaction of NRF2 with PPIA, inducing NRF2 ubiquitination and degradation. Interestingly, CsA interrupts glutamine metabolism mediated by the NRF2/KLF5/SLC1A5 pathway, consequently suppressing the growth of NRF2-hyperactivated NSCLC cells. CsA and a glutaminase inhibitor combination therapy signiﬁcantly retard tumor progression in NSCLC patient-derived xenograft (PDX) models with NRF2 hyperactivation. Our study demonstrates that targeting NRF2 protein stability is an actionable therapeutic approach to treat NRF2-hyperactivated NSCLC.  \nThe transcription factor NRF2 (nuclear factor erythroid 2-related factor 2) and its negative regulator KEAP1 (Kelch Like ECH Associated Protein 1) contribute profoundly to the maintenance of the cellular redox homeostasis1. Under oxidative and electrophilic stress, NRF2 is released from KEAP1 and translocated to the nucleus to initiate the transcription of the antioxidant program2. This transient and inducible response was recognized originally as a protective mechanism against tumorigenesis3. However, many studies have subsequently indicated that constitutive NRF2 activation exhibits potent pro-tumorigenic properties in many types of cancer4, including lung cancer.  \nPan-cancer genome analysis of The Cancer Genome Atlas (TCGA) revealed that NRF2 activation was particularly enhanced in non-small cell  \nlung cancer (NSCLC)5. Genomic alterations that activated the NRF2 pathway ranked as the third most common in lung adenocarcinoma (LUAD, 25%), largely due to loss-of-function mutations in KEAP16. Also, KRAS oncogenic mutations, the most prevalent oncogenic drivers in LUAD, potentiate transcriptional activation of NRF27. KEAP1 mutations co-exist in approximately 20% of KRAS-mutant LUAD8. Activated NRF2 not only promotes lung tumorigenesis through maintaining redox homeostasis and detoxiﬁcation of reactive oxygen species (ROS)7, but also facilitates aggressive lung cancer via multiple pro-metastasis factors6,9. Collectively, these comprehensive studies have established abnormal NRF2 activation as a pivotal oncogenic driver in lung cancer, implying a potential beneﬁt of targeting NRF2 in cancer therapy.  \nA full list of afﬁliations appears at the end of the paper. [e-mail:](e-mail: wqlu@bio.ecnu.edu.cn)[ wqlu@bio.ecnu.edu.cn](e-mail: wqlu@bio.ecnu.edu.cn); [huangjin@ecust.edu.cn](huangjin@ecust.edu.cn)  \nHowever, targeted therapies that directly inhibit NRF2 remain inaccessible, emphasizing the necessity of exploring an alternative strategy.  \nIn this study, we exp","cbCailaCXxbOkmf1","https://ap.wps.com/l/cbCailaCXxbOkmf1","pdf",5630025,"English","# Introduction\n## Targeting NRF2 hyperactivation in non-small cell lung cancer\n# Results\n## Identification and validation of Cyclosporin A (CsA) as a chemical inducer of targeted NRF2 protein degradation\n## Screening strategy for compounds regulating NRF2 protein stability","[{\"question\":\"What role does PPIA play in NRF2 regulation?\",\"answer\":\"PPIA is required for NRF2 protein stability. When PPIA is ablated, NRF2 is degraded more readily and NRF2-driven growth in NSCLC cells is blocked.\"},{\"question\":\"How does PPIA protect NRF2 from ubiquitin-mediated degradation?\",\"answer\":\"PPIA physically binds NRF2 and blocks ubiquitin/KEAP1 access to NRF2, thereby preventing ubiquitin-mediated degradation.\"},{\"question\":\"What effect does cyclosporin A (CsA) have on NRF2 and lung cancer cells?\",\"answer\":\"CsA impairs the NRF2–PPIA interaction, inducing NRF2 ubiquitination and degradation. It also disrupts NRF2-linked glutamine metabolism via the NRF2/KLF5/SLC1A5 pathway, suppressing growth of NRF2-hyperactivated NSCLC models.\"}]","PPIA dictates NRF2 stability to promote lung cancer progression | PDF",1790048552,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cc3a722c0d2ecea3f502b7692e51e42.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cb5ebe52cd44eee7be4a50c73c665bc.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa05a2fdff0331e78ae5b42aa811f9b5.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a71775805c870e7c1d0cd3b1887b73fb.webp",980,1301]